Screener
Revolution Medicines, Inc. RVMD Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(453,816) | $(213,416) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of intangible assets | — | 267 |
| Stock-based compensation expense | 87,299 | 25,084 |
| Depreciation and amortization | 2,346 | 1,692 |
| Change in fair value of warrant liability | 15,788 | (2,439) |
| Non-cash interest expense on liabilities related to sale of future royalties | 12,197 | — |
| Net amortization of premium or discount on marketable securities | (3,223) | (9,817) |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s stock-based comp?
- Revolution Medicines, Inc. (RVMD) reported stock-based comp of $87.3M in Q1 2026.
- How has Revolution Medicines, Inc.'s stock-based comp changed year-over-year?
- Revolution Medicines, Inc.'s stock-based comp increased by 248.0% year-over-year, from $25.08M to $87.3M.
- What is the long-term trend for Revolution Medicines, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s stock-based comp has grown at a 54.6% compound annual growth rate (CAGR), from $20.72M to $118.39M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Revolution Medicines, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude